| Primary |
| Hepatitis C |
14.3% |
| Renal Cancer |
13.6% |
| Renal Cell Carcinoma |
13.5% |
| Metastatic Renal Cell Carcinoma |
9.8% |
| Hypertension |
6.9% |
| Pain |
5.7% |
| Diabetes Mellitus |
5.2% |
| Malignant Melanoma |
4.8% |
| Prophylaxis |
4.5% |
| Drug Use For Unknown Indication |
4.1% |
| Paraesthesia |
3.3% |
| Asthma |
2.1% |
| Hypothyroidism |
1.9% |
| Neoplasm Malignant |
1.7% |
| Hypercholesterolaemia |
1.6% |
| Pain Management |
1.6% |
| Arrhythmia |
1.4% |
| Arthralgia |
1.4% |
| Chronic Myeloid Leukaemia |
1.4% |
| Ascites |
1.2% |
|
| Depression |
9.6% |
| Haemoptysis |
8.0% |
| Parkinsonism |
8.0% |
| Pulmonary Embolism |
7.2% |
| Hypertension |
6.4% |
| Tremor |
6.4% |
| Dehydration |
5.6% |
| Nephrotic Syndrome |
5.6% |
| Peripheral Ischaemia |
5.6% |
| Retinopathy |
5.6% |
| White Blood Cell Count Decreased |
4.8% |
| Tumour Haemorrhage |
4.0% |
| Asthenia |
3.2% |
| Granulomatous Liver Disease |
3.2% |
| Hyperkalaemia |
3.2% |
| Hypothyroidism |
3.2% |
| Myalgia |
3.2% |
| Gastrointestinal Perforation |
2.4% |
| Lacunar Infarction |
2.4% |
| Myelodysplastic Syndrome |
2.4% |
|
| Secondary |
| Renal Cell Carcinoma |
21.6% |
| Hepatitis C |
15.5% |
| Drug Use For Unknown Indication |
9.1% |
| Metastatic Renal Cell Carcinoma |
7.6% |
| Renal Cancer |
6.9% |
| B-cell Lymphoma |
5.8% |
| Prophylaxis |
4.0% |
| Hypertension |
3.9% |
| Hodgkin's Disease |
2.9% |
| Malignant Melanoma |
2.8% |
| Multiple Myeloma |
2.8% |
| Diabetes Mellitus |
2.7% |
| Langerhans' Cell Granulomatosis |
2.4% |
| Product Used For Unknown Indication |
2.4% |
| Lymphoma |
2.0% |
| Anaemia |
1.9% |
| Depression |
1.7% |
| Pain |
1.5% |
| Chronic Myeloid Leukaemia |
1.4% |
| Metastatic Malignant Melanoma |
1.1% |
|
| Anaemia |
8.8% |
| Tremor |
8.8% |
| Pyrexia |
7.9% |
| Sepsis |
7.4% |
| Injection Site Abscess |
5.6% |
| Peritonitis |
5.6% |
| Renal Failure |
5.1% |
| Transaminases Increased |
5.1% |
| Septic Shock |
4.7% |
| White Blood Cell Count Decreased |
4.7% |
| Death |
4.2% |
| Hyperkalaemia |
4.2% |
| Dizziness |
3.7% |
| Myalgia |
3.7% |
| Pneumonia |
3.7% |
| Rash |
3.7% |
| Ascites |
3.3% |
| Myelodysplastic Syndrome |
3.3% |
| Osteonecrosis |
3.3% |
| Pulmonary Embolism |
3.3% |
|
| Concomitant |
| Metastatic Renal Cell Carcinoma |
49.2% |
| Renal Cell Carcinoma |
6.3% |
| Hepatitis C |
5.9% |
| Product Used For Unknown Indication |
5.9% |
| Prophylaxis |
4.8% |
| Drug Use For Unknown Indication |
4.8% |
| Multiple Myeloma |
3.0% |
| Metastases To Bone |
2.8% |
| Idiopathic Thrombocytopenic Purpura |
2.7% |
| Hypertension |
2.5% |
| Chronic Myeloid Leukaemia |
2.3% |
| Anaemia |
1.3% |
| Eczema |
1.2% |
| Sedation |
1.2% |
| Renal Cell Carcinoma Stage Iv |
1.1% |
| Diabetes Mellitus |
1.1% |
| Pain |
1.0% |
| Liver Transplant |
1.0% |
| Peritonitis |
1.0% |
| Medical Diet |
0.9% |
|
| Neoplasm Malignant |
11.0% |
| Rash |
10.1% |
| Stomatitis |
7.0% |
| White Blood Cell Count Decreased |
7.0% |
| Pyrexia |
6.1% |
| Skin Ulcer |
5.7% |
| Thrombocytopenia |
5.3% |
| Anaemia |
4.4% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
4.4% |
| Haemoglobin Decreased |
3.9% |
| Liver Disorder |
3.9% |
| Sepsis |
3.9% |
| Weight Increased |
3.9% |
| Interstitial Lung Disease |
3.5% |
| Malignant Neoplasm Progression |
3.5% |
| Platelet Count Decreased |
3.5% |
| Viral Infection |
3.5% |
| Vomiting |
3.5% |
| Tumour Haemorrhage |
3.1% |
| C-reactive Protein Increased |
2.6% |
|
| Interacting |
| Drug Use For Unknown Indication |
21.4% |
| Hepatitis C |
14.3% |
| Malignant Melanoma |
14.3% |
| Diabetes Mellitus |
7.1% |
| Erectile Dysfunction |
7.1% |
| Glaucoma |
7.1% |
| Hyperlipidaemia |
7.1% |
| Hypertriglyceridaemia |
7.1% |
| Product Used For Unknown Indication |
7.1% |
| Psoriatic Arthropathy |
7.1% |
|
| Drug Interaction |
14.3% |
| Hepatic Enzyme Increased |
14.3% |
| Hepatic Neoplasm Malignant |
14.3% |
| Hepatitis |
14.3% |
| Hypothyroidism |
14.3% |
| Thrombocytopenia |
14.3% |
| Visual Field Defect |
14.3% |
|
